Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
Date:7/7/2009

ommercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

ZOMETA is a registered trademark of Novartis Oncology.

*Editors Note: The FDA has provisionally approved the trade name Prolia(TM) for the proposed indications of treatment and prevention of osteoporosis in postmenopausal women, and treatment and prevention of bone loss in patients undergoing hormone ablation for non-metastatic prostate or breast
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
4. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
5. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
6. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
7. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Zimmer Holdings, Inc. (NYSE ... fixation system for trauma patients. Available in ... ® External Fixation System from Zimmer is a ... materials.   The XtraFix System allows surgeons ... the external fixation process, resulting in saved time, costs and ...
(Date:3/27/2015)... , March 27, 2015 ... International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare, ... senior service industry, will be held at Shanghai New ... On 25 February, 2015,  Implementation Suggestions on Encouraging Private ... Industry, which was jointly issued by the Ministry of ...
(Date:3/27/2015)... March 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... of its previously announced registered offering of common shares ... "Offering"). Pursuant to the Offering, the Company issued 7,286,432 ... for aggregate gross proceeds of approximately $1.45 billion. On ... Securities and Exchange Commission a final prospectus supplement to ...
Breaking Medicine Technology:Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3
... Jan. 12, 2011 CredenceHealth announced today ... for Meaningful Use in Clinical Quality Measures (i.e. eMeasures). ... receive this stand-alone certification. " CCHIT ... so that companies are now able to offer these ...
... INDIANAPOLIS, Jan. 12, 2011 Eli Lilly and Company ... and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted ... enzyme replacement therapy (PERT), currently under FDA review for ... During the meeting, the committee had questions about ...
Cached Medicine Technology:CredenceHealth's CHlive Meaningful Use Certified (ONC-ATCB 2011/2012 Certification) 2CredenceHealth's CHlive Meaningful Use Certified (ONC-ATCB 2011/2012 Certification) 3Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency 2
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s ... the Chesapeake Conference Center in Chesapeake, Virginia. Each year, ... for women in the Hampton Roads region. The 2015 ... Lives. Women grow stronger through sharing their stories and ... year the WWC™ theme is T-talk where we will share ...
(Date:3/27/2015)... March 27, 2015 The Monogamy ... dating experts Samantha Sanderson and Jason Rogers has just ... of media attention. The commotion surrounding the course's launch ... him to publish an in-depth review of the new ... the men in their lives suddenly start pulling away ...
(Date:3/27/2015)... The federal court overseeing thousands of ... medication increases the risk that a patient will develop ... Dismiss four individual cases that had been filed in ... in the U.S. District Court, District of South Carolina, ... were warranted because the plaintiffs in those claims had ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 Healthpointe ... Stanley G. Katz, M.D., is now treating knee and ... including Anaheim , Long Beach, and La Mirada. ... of acute knee and hip joint disorders as well ... Katz is passionate in returning his patients back to ...
Breaking Medicine News(10 mins):Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3
... Sept. 23 PharmAthene, Inc. (NYSE Amex: PIP ... chemical threats, announced today that management will present at the ... to present on Tuesday, September 29(th) 2009 at 11:00 a.m. ... New York City. , PharmAthene,s presentation will be webcast ...
... PAUL, Minn., Sept. 23 Prime Therapeutics (Prime), a nationwide pharmacy ... the organization as senior vice president of human resources. , ... all areas of human resources, facilities, safety and security management. ... to our executive team," said Kim Mageau, interim president and CEO ...
... , RENO, NV, Sept. 23 /PRNewswire-FirstCall/ - (Pinksheets: CMHS) ... its Articles of Incorporation to change the Company,s name ... part of the Company,s previously announced plans to change ... of profitable clean energy fields (such as natural gas) ...
... , , , ... Program , , - SDA, CDC Initiative Encourages Hygiene ... York Students Also Recognized , , WASHINGTON, Sept. 23 ... One group of students hit the science lab. A language arts class used the ...
... MO, 23 September 2009 Elsevier, a leading ... and services announced today, that the Editors of ... the foremost publication of information about evidence-based dental ... to its recognized experts and valued peer reviewers. ...
... are part of an international team that has discovered ... with hepatitis C who are most likely to benefit ... Max Moldovan from the institute,s Bioinformatics division worked with ... analyse the genomes of more than 800 people, including ...
Cached Medicine News:Health News:Prime Therapeutics Hires Jacqueline Chase as Senior Vice President of Human Resources 2Health News:CMHS (dba Hybrid Energy Holdings) changes name of corporation and prepares to file for ticker symbol change with FINRA 2Health News:'Bubble Trouble' Team Hits the Lab for Good Hygiene 2Health News:'Bubble Trouble' Team Hits the Lab for Good Hygiene 3Health News:'Bubble Trouble' Team Hits the Lab for Good Hygiene 4Health News:Journal of Evidence-Based Dental Practice to offer continuing education units for reviewers 2Health News:Discovery could improve hepatitis C treatment 2
... STA R is a fully ... for clotting, chromogenic and immunological, latex ... analyser using standard 5-position racks as ... 200 different methods, up to 70 ...
... Surgicutt family of bleeding time devices provides ... adults, Surgicutt Jr. for children and Surgicutt ... family is engineered to perfect the bleeding ... the variables that have previously hindered test ...
... tenderfoot infant heelstick device uses a highly sharpened ... a gentle arc. The incision produced is carefully ... where most nerve fibers are located, but through ... high quality blood sample with significantly less pain ...
The Unistik 3 family of single use safety lancets has 4 models for use across all clinical environments....
Medicine Products: